Table 4 Demographic and angiography characteristics of patients in derivation and clinical effect cohort.
From: Bifurcation functional significance score as predictor of mortality: a validating study
Patient characteristics | Derivation cohort (n = 81) | Clinical effect cohort (n = 555) | P-value |
|---|---|---|---|
Age (years) | 65 ± 11 | 67 ± 10 | 0.337 |
Sex—males, n (%) | 57 (71) | 383 (69) | 0.646 |
Hyperlipidemia, n (%) | 74 (91) | 522 (94) | 0.162 |
Diabetes, n (%) | 36 (45) | 216 (39) | 0.401 |
Renal failure, n (%) | 24 (30) | 172 (31) | 0.941 |
Smoking, n (%) | 45 (56) | 222 (40) | 0.054 |
Cerebrovascular disease, n (%) | 13 (16) | 83 (15) | 0.661 |
Peripheral artery disease, n (%) | 9 (11) | 55 (10) | 0.635 |
Previous myocardial infarction, n (%) | 22 (27) | 144 (26) | 0.644 |
Previous PCI, n (%) | 46 (57) | (48) | 0.183 |
Beta blocker, n (%) | 72 (89) | (88) | 0.685 |
ACE inhibitor/ ARB, n (%) | 71 (88) | (84) | 0.578 |
Calcium antagonist, n (%) | 45 (55) | (39) | 0.019 |
Atrial fibrillation, n (%) | 14 (17) | (22) | 0.546 |
Angiographic parameters | |||
SYNTAX score | 13 ± 4 | 12 ± 6 | 0.405 |
MV RVD, mm | 3.32 ± .29 | 3.33 ± .43 | 0.421 |
MV %DS pre, % | 61 ± 22 | 54 ± 31 | 0.103 |
MV %DS final, % | 1 ± 6 | 2 ± 7 | 0.334 |
MB RVD, mm | 2.96 ± .23 | 3.08 ± .75 | 0.593 |
MB %DS pre, % | 71 ± 13 | 65 ± 27 | 0.090 |
MB %DS final, % | 1 ± 4 | 2 ± 10 | 0.012 |
SB RVD, mm | 2.43 ± .32 | 2.36 ± .74 | 0.561 |
SB %DS pre, % | 56 ± 25 | 49 ± 32 | 0.062 |
SB %DS final, % | 33 ± 33 | 28 ± 31 | 0.172 |
Lesion length, mm | 43 ± 20 | 35 ± 20 | 0.004 |
MB BARI score, % | 30 ± 9 | 29 ± 8 | 0.277 |
SB BARI score, % | 16 ± 6 | 12 ± 60 | 0.001 |
Multivessel disease, n (%) | 42 (52) | 361 (65) | 0.021 |
Bifurcation Functional Significance Score | 9 ± 2 | 7 ± 3 | 0.001 |
